Verrica Pharmaceuticals Inc.
VRCA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $36 | $332 | $94 | $248 |
| - Cash | $46 | $70 | $34 | $16 |
| + Debt | $46 | $46 | $2 | $43 |
| Enterprise Value | $36 | $308 | $61 | $275 |
| Revenue | $8 | $5 | $9 | $12 |
| % Growth | 47.7% | -43.3% | -24.7% | – |
| Gross Profit | $5 | $4 | $8 | $12 |
| % Margin | 63.8% | 85.4% | 92% | 96.1% |
| EBITDA | -$66 | -$62 | -$22 | -$30 |
| % Margin | -871% | -1,213.8% | -239.1% | -252.6% |
| Net Income | -$77 | -$67 | -$24 | -$35 |
| % Margin | -1,012.1% | -1,307.5% | -271.1% | -292.3% |
| EPS Diluted | -14.78 | -14.78 | -7.17 | -12.97 |
| % Growth | 0% | -106.1% | 44.7% | – |
| Operating Cash Flow | -$61 | -$39 | -$19 | -$28 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$1 |
| Free Cash Flow | -$61 | -$39 | -$19 | -$28 |